Stock Events

Stock Events

Cellectis 

€2.8
100
-€0.04-1.23% Thursday 06:05

Statistics

Day High
2.8
Day Low
2.8
52W High
4.66
52W Low
1.03
Volume
-
Avg. Volume
-
Mkt Cap
202.51M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30AprExpected
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Next
-0.28
-0.18
-0.09
0.01
Expected EPS
-0.26019625622
Actual EPS
N/A

Financials

-87.54%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
78.65MRevenue
-68.85MNet Income

Analyst Ratings

$6.45Average Price Target
The highest estimate is 6.83.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ZVA.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.75B
CRISPR Therapeutics is directly competing in the gene editing space, focusing on CRISPR/Cas9 technology, similar to Cellectis' TALEN technology for gene editing in therapeutics.
Editas Medicine
EDIT
Mkt Cap261.32M
Editas Medicine operates in the genome editing field, utilizing CRISPR technology to modify genes, directly competing with Cellectis' gene editing therapies.
Intellia Therapeutics
NTLA
Mkt Cap1.55B
Intellia Therapeutics is a competitor in the CRISPR/Cas9 genome editing technology, offering therapies that could potentially overlap with Cellectis' market in gene-edited treatments.
Sangamo Therapeutics
SGMO
Mkt Cap124.32M
Sangamo Therapeutics focuses on genomic medicine, including gene editing and gene therapy, competing with Cellectis in the development of gene-modified cell-based treatments.
Allogene Therapeutics
ALLO
Mkt Cap604.57M
Allogene Therapeutics specializes in allogeneic CAR T-cell therapies, which competes with Cellectis' approach to off-the-shelf CAR T-cell products.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the CAR T-cell therapy space, directly challenging Cellectis' CAR T-cell product pipeline.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.67B
BioMarin Pharmaceutical focuses on gene therapy for genetic diseases, a field that indirectly competes with Cellectis' gene editing technologies for therapeutic applications.
Pfizer
PFE
Mkt Cap161.09B
Pfizer is involved in biopharmaceuticals, including investments in gene therapy and immunotherapy, areas that compete with Cellectis' focus on gene-edited immunotherapies.
Novartis
NVS
Mkt Cap297.32B
Novartis has a strong presence in gene therapy and CAR T-cell therapy, including the first FDA-approved CAR T-cell therapy, competing with Cellectis in the advanced therapy medicinal products space.

About

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company was founded in 1999 and is headquartered in Paris, France.
Show more...
CEO
Dr. Andre Choulika Ph.D.
Employees
224
Country
DE
ISIN
FR0010425595
WKN
000A0MKPR

Listings

F
DE
ZVAA.F
XNAS
US
CLLS
F
DE
ZVA.F
PA
FR
ALCLS.PA

0 Comments

Share your thoughts

FAQ

What is Cellectis stock price today?▼
The current price of ZVA.F is €2.8 EUR — it has decreased by -1.23% in the past 24 hours. Watch Cellectis stock price performance more closely on the chart.
What is Cellectis stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Cellectis stocks are traded under the ticker ZVA.F.
Is Cellectis stock price growing?▼
ZVA.F stock has risen by +1.08% compared to the previous week, the month change is a -15.15% fall, over the last year Cellectis has showed a +146.91% increase.
What is Cellectis market cap?▼
Today Cellectis has the market capitalization of 202.51M
When is the next Cellectis earnings date?▼
Cellectis is going to release the next earnings report on April 30, 2026.
What were Cellectis earnings last quarter?▼
ZVA.F earnings for the last quarter are 0.01 EUR per share, whereas the estimation was -0.2 EUR resulting in a +104.37% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Cellectis revenue for the last year?▼
Cellectis revenue for the last year amounts to 78.65M EUR.
What is Cellectis net income for the last year?▼
ZVA.F net income for the last year is -68.85M EUR.
How many employees does Cellectis have?▼
As of April 06, 2026, the company has 224 employees.
In which sector is Cellectis located?▼
Cellectis operates in the Health Care sector.
When did Cellectis complete a stock split?▼
Cellectis has not had any recent stock splits.
Where is Cellectis headquartered?▼
Cellectis is headquartered in Paris, DE.